AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7647378 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+ (n = 64)
Number of subjects: 126
Study 7647378 — intervention group
Group type: COMPARATOR
Intervention: Control (no platelet pheresis, n = 52)
Number of subjects: 126
Study 7647378 — intervention group
Group type: EXPERIMENTAL
Intervention: PRPc (n = 10)
Number of subjects: 126
Study 7647378 — intervention group
Group type: EXPERIMENTAL
Intervention: BBP (Blood Bank Platelets)
Number of subjects: 126
Study 7647378 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+
Number of subjects: 126
Study 2650586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen capsule
Number of subjects: 305
Study 2650586 — intervention group
Group type: COMPARATOR
Intervention: Clemastine tablet
Number of subjects: 305
Study 687051 — intervention group
Group type: EXPERIMENTAL
Intervention: Diapulse
Number of subjects: 300
Study 687051 — intervention group
Group type: EXPERIMENTAL
Intervention: Curapuls
Number of subjects: 300
Study 687051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 30918997 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic repair of lateral ankle ligament complex
Number of subjects: 0
Study 30918997 — intervention group
Group type: COMPARATOR
Intervention: Open repair of lateral ankle ligament complex
Number of subjects: 0
Study 30918997 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment
Number of subjects: 0
Study 30918997 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 28695477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of xylometazoline and dexpanthenol
Number of subjects: 152
Study 28695477 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline monotherapy
Number of subjects: 152
Study 26043895 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 486
Study 26043895 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 486
Study 23859719 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in midarm circumference (MAC)
Number of subjects: 1846
Study 23859719 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in skinfold measurements
Number of subjects: 1846
Study 23859719 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in MAC and skinfold measurements in patients with BMI ≤25 kg/m2
Number of subjects: 1846
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorders
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood disorders
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic disorders
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial personality disorder
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorders (SUDs)
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric medications
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment eligibility
Number of subjects: 111
Study 21679262 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory
Number of subjects: 111
Study 21179917 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening (at bedtime) administration of Prestarium (perindopril) 10 mg, Tarka (180 mg verapamil hydrochloride/2 mg trandolapril), Norvasc (amlodipine besilat) 10 mg
Number of subjects: 60
Study 21179917 — intervention group
Group type: COMPARATOR
Intervention: Morning (at awakening) administration of Prestarium (perindopril) 10 mg, Tarka (180 mg verapamil hydrochloride/2 mg trandolapril), Norvasc (amlodipine besilat) 10 mg
Number of subjects: 60
Study 17338681 — intervention group
Group type: EXPERIMENTAL
Intervention: Living fibroblasts (20 million/mL)
Number of subjects: 215
Study 17338681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transport medium without living cells)
Number of subjects: 215
Study 15957201 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated housing services
Number of subjects: 121
Study 15957201 — intervention group
Group type: COMPARATOR
Intervention: Parallel housing services
Number of subjects: 121
Study 12131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water irrigation with One-Step bonding agent
Number of subjects: 40
Study 12131885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl irrigation with One-Step bonding agent
Number of subjects: 40
Study 12131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered water irrigation with One-Step bonding agent
Number of subjects: 40
Study 12131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline irrigation with One-Step bonding agent
Number of subjects: 40
Study 12131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline irrigation with Solo bonding agent
Number of subjects: 40
Study 12131885 — intervention group
Group type: COMPARATOR
Intervention: Tap water irrigation (control) with all bonding agents
Number of subjects: 40
Study 12131885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water irrigation with Prime & Bond or Single Bond Adhesive
Number of subjects: 40
Study 9541523 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary phylloquinone to 420 microg/day with fortified corn oil, split between lunch and dinner meals.
Number of subjects: 9
Study 9541523 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet containing 100 microg of phylloquinone (baseline).
Number of subjects: 9
Study 8004880 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 17.5 micrograms/kg
Number of subjects: 15
Study 8004880 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 35 micrograms/kg
Number of subjects: 15
Study 8004880 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa 70 micrograms/kg
Number of subjects: 15
Study 8004880 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 15
Study 2681610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan fluid (viscoelastic solution)
Number of subjects: 55
Study 29396219 — intervention group
Group type: COMPARATOR
Intervention: Active control (household visits to measure mid-upper-arm circumference)
Number of subjects: 8246
Study 29396219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (counselling on appropriate maternal, infant, and young child feeding plus small-quantity lipid-based nutrient supplements from 6-24 months)
Number of subjects: 8246
Study 29396219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, handwashing, and nutrition intervention
Number of subjects: 8246
Study 29396219 — intervention group
Group type: EXPERIMENTAL
Intervention: Water intervention
Number of subjects: 8246
Study 29396219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention
Number of subjects: 8246
Study 29396219 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing intervention
Number of subjects: 8246
Study 29396219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water, sanitation, and handwashing intervention
Number of subjects: 8246
Study 27181576 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 0
Study 27181576 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 25786484 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive heat stress
Number of subjects: 29
Study 23833856 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine
Number of subjects: 200
Study 23833856 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 200
Study 23833856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 200
Study 23833856 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 200
Study 19442970 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational DVD
Number of subjects: 131
Study 19442970 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure
Number of subjects: 131
Study 18371481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238
Study 18371481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study 16022925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 94
Study 16022925 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 94
Study 12692460 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture
Number of subjects: 18
Study 12692460 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at 2 Hz
Number of subjects: 18
Study 12692460 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at 20 Hz
Number of subjects: 18
Study 12692460 — intervention group
Group type: COMPARATOR
Intervention: Direct visual stimulation
Number of subjects: 18
Study 10553483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain patients (CBP)
Number of subjects: 60
Study 10553483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension headache patients (THA)
Number of subjects: 60
Study 10553483 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 60
Study 8534483 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 500 micrograms twice daily for 4 months
Number of subjects: 0
Study 8534483 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 4 months
Number of subjects: 0
Study 1810682 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg sublingually after 1 hour of nitroglycerin (3 mg/h) and heparin (1200 IU/h) infusion
Number of subjects: 10
Study 1810682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7069074 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 84
Study 7069074 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 84
Study 7069074 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 84
Study 7069074 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine decongestant (carbinoxamine maleate-pseudoephedrine HCl)
Number of subjects: 84
Study 30633040 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable products (injection every 2-3 months)
Number of subjects: 536
Study 30633040 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tablet
Number of subjects: 536
Study 30633040 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injections
Number of subjects: 536
Study 30633040 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ring
Number of subjects: 536
Study 30633040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipurpose prevention technologies (combining HIV and pregnancy protection)
Number of subjects: 536
Study 29162058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation therapy (CRT)
Number of subjects: 120
Study 29162058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 120
Study 29162058 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 120
Study 27991419 — intervention group
Group type: EXPERIMENTAL
Intervention: Comet
Number of subjects: 961
Study 27991419 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years (IY)
Number of subjects: 961
Study 27991419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cope
Number of subjects: 961
Study 27991419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 961
Study 27991419 — intervention group
Group type: COMPARATOR
Intervention: Connect
Number of subjects: 961
Study 27991419 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 961
Study 27991419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of Comet
Number of subjects: 961
Study 27991419 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 961
Study 25122448 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with past direct-personal trauma
Number of subjects: 65
Study 25122448 — intervention group
Group type: COMPARATOR
Intervention: Participants without past direct-personal trauma
Number of subjects: 65
Study 21924396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone followed 6 hours later by oxytocin infusion
Number of subjects: 450
Study 21924396 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 450
Study 19152338 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-focused group intervention
Number of subjects: 235
Study 19152338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 235
Study 17606658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 400
Study 17606658 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100-800 mg/day)
Number of subjects: 400
Study 17606658 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-4 mg/day)
Number of subjects: 400
Study 16234442 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% at night
Number of subjects: 167
Study 16234442 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees SLT
Number of subjects: 167
Study 16234442 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 degrees SLT
Number of subjects: 167
Study 16234442 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees SLT
Number of subjects: 167
Study 12039111 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (up to two 800 microg doses vaginally)
Number of subjects: 50
Study 12039111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10536064 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily administration of budesonide (200-400 microg/day)
Number of subjects: 206
Study 10536064 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily administration of budesonide (200-400 microg/day)
Number of subjects: 206
Study 10536064 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both treatments
Number of subjects: 206
Study 10536064 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary efficacy measures
Number of subjects: 206
Study 7477799 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute EEG recording under vigilance-controlled condition
Number of subjects: 0
Study 7477799 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute EEG recording under resting condition
Number of subjects: 0
Study 7477799 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer EEG recording duration
Number of subjects: 0
Study 7477799 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute EEG recording
Number of subjects: 0
Study 2203254 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (1.0 g protein.kg body wt‐1.d‐1)
Number of subjects: 2
Study 2203254 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein diet (0.6 g protein.kg body wt‐1.d‐1)
Number of subjects: 2
Study 6992927 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day)
Number of subjects: 100
Study 6992927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31372871 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral reproductive research study participation
Number of subjects: 44
Study 29507752 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 0
Study 29507752 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 29507752 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 27028008 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan recommendations (social normative, physician, government)
Number of subjects: 656
Study 27028008 — intervention group
Group type: EXPERIMENTAL
Intervention: Government or providers recommending the lowest cost plan
Number of subjects: 656
Study 27028008 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no recommendations)
Number of subjects: 656
Study 25194963 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR) - low-calorie, high soy-protein drink with a low glycemic index
Number of subjects: 42
Study 25194963 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle Intervention (LS) - dietary counseling sessions and increased physical activity
Number of subjects: 42
Study 22348981 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated implants with a thin fibrinogen layer containing 2 bisphosphonates
Number of subjects: 16
Study 22348981 — intervention group
Group type: COMPARATOR
Intervention: Untreated implants
Number of subjects: 16
Study 22348981 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated implants
Number of subjects: 16
Study 20228219 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound herbal preparation (CHP)
Number of subjects: 120
Study 20228219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study 18265662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard interferon-alpha (9/10 MU) three times a week plus lamivudine 100mg daily for 52 weeks
Number of subjects: 37
Study 18265662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy after combination therapy
Number of subjects: 37
Study 18265662 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard interferon-alpha plus lamivudine
Number of subjects: 37
Study 18265662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 37
Study 18265662 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antiviral maintenance therapy
Number of subjects: 37
Study 14872247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea condition (hot brewed tea as a major part of fluid intake)
Number of subjects: 13
Study 14872247 — intervention group
Group type: COMPARATOR
Intervention: No tea condition (tea excluded from the diet)
Number of subjects: 13
Study 11196521 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 1 g/day
Number of subjects: 130
Study 11196521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 9853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Early elective open surgery (n=563)
Number of subjects: 1090
Study 9853436 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic surveillance (n=527)
Number of subjects: 1090
Study 7916401 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoramidon (inhibitor of endothelin converting enzyme)
Number of subjects: 0
Study 7916401 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (selective endothelin receptor A antagonist)
Number of subjects: 0
Study 7916401 — intervention group
Group type: EXPERIMENTAL
Intervention: Proendothelin-1 (precursor to endothelin-1)
Number of subjects: 0
Study 7916401 — intervention group
Group type: COMPARATOR
Intervention: Endothelin-1
Number of subjects: 0
Study 2816360 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment for 6 months
Number of subjects: 13
Study 2816360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 5000 IU s. c. heparin daily (starting preoperatively)
Number of subjects: 178
Study 1215880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 178
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in males
Number of subjects: 178
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in females
Number of subjects: 178
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in patients under 60 years
Number of subjects: 178
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in obese patients
Number of subjects: 178
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in patients with predisposing factors
Number of subjects: 178
Study 1215880 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin side effects
Number of subjects: 178
Study 31390762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined synbiotics and BCAAs treatment
Number of subjects: 61
Study 31390762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28472667 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐LED (blue-depleted circadian-sensitive light)
Number of subjects: 16
Study 28472667 — intervention group
Group type: COMPARATOR
Intervention: FL (standard fluorescent light)
Number of subjects: 16
Study 25600221 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 24
Study 25600221 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppb ozone
Number of subjects: 24
Study 25600221 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb ozone
Number of subjects: 24
Study 23507791 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (high-dose group, n = 20)
Number of subjects: 53
Study 23507791 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone acetonide (low-dose group, n = 20)
Number of subjects: 53
Study 23507791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 53
Study 21499192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg) 1 week before vitrectomy
Number of subjects: 35
Study 21499192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 35
Study 19335800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine hydrochloride 10% spray
Number of subjects: 81
Study 19335800 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lidocaine hydrochloride 10% spray
Number of subjects: 81
Study 19335800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 17037894 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 36